A University of Kentucky College of Medicine professor has been awarded a $1.9 million NIH grant for his research on the body’s immune response to sepsis, which could potentially help to improve therapies for the common disease.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have found a major molecular “switch” that controls how cells turn their genes on and off. This process ensures the cell correctly and adequately performs its assigned tasks in the body. The research team’s discovery will likely improve the understanding of how normal stem cells function, and could possibly lead to insights into disease.
New resource from NCCN helps cancer patients and caregivers recognize and understand blood cell production deficiencies, to better participate in their care planning; available for free at NCCN.org/patientguidelines.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
A combination of inexpensive oral medications may be able to treat fatigue-inducing anemias caused by chronic diseases and inflammation, a new discovery from the University of Virginia School of Medicine suggests.
Tourniquet use has been consistently increasing in Los Angeles County since 2015 and is significantly associated with improved patient survival.
Penn Medicine researchers discovered that less is more when it comes to the length of what is known as the single-chain variable fragment in CAR T cells.
A real-life forensic puzzle inspired University of Illinois at Chicago and Iowa State University researchers to explore the physics involved, and in Physics of Fluids, they present theoretical results revealing an interaction of the incoming vortex ring of propellant muzzle gases with backward blood spatter. A detailed analytical theory of such turbulent self-similar vortex rings was given by this group in earlier work and is linked mathematically to the theory of quantum oscillators.
Researchers from Rutgers Cancer Institute of New Jersey, recently discovered that a mitochondrial uncoupling drug is toxic against leukemic cells, revealing a potential therapeutic strategy against T-ALL.
The first large-scale, multi-hospital evaluation of an “all or none” federal policy intended to improve results in sepsis patients finds that the guidelines are a wash – on average they neither helped nor hurt outcomes despite significant investments in their implementation.
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer.
Only a few treatment options exist for sickle cell patients. Today, researchers report discovery of a small molecule that could treat sickle cell disease by boosting levels of fetal hemoglobin, a healthy form that adults normally do not make. They will present their results at ACS Spring 2021.
Surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases.
The risk of childhood leukemia among kids with Down syndrome is higher than predicted, according to a new study led by UC Davis and UC San Francisco researchers. Early diagnosis remains critical.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime. While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders and offers a promising blood test aimed at a precision-medicine approach to treatment.
During GVN’s 9th International Meeting in Melbourne, Australia on September 25-27, 2017 in partnership with the Peter Doherty Institute and the Institut Pasteur, researchers held impressive sessions on one of the most potent human carcinogens, human T cell leukemia virus-1 (HTLV-1).
UC San Diego researchers discovered that patient survival from sepsis is associated with higher platelet counts, and identified two currently available drugs that protect these blood cells and improve survival in mice with sepsis.
Blood from critically ill COVID-19 patients contains antibodies that can contribute to clotting. These antibodies form immune complexes that activate platelets, the cells that lead to blood clot formation. Some blood-thinner medications can block these immune complexes and potentially reduce clots.
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
Expert from Rutgers Cancer Institute of New Jersey shares information on symptoms, treatment and more to highlight multiple myeloma awareness month.
Only 3% of patients at high risk for primary aldosteronism (PA), a common disorder that causes high blood pressure and can lead to heart and kidney complications, are screened for the condition, according to a study that will be presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Electric stimulation may be able to help blood vessels carry white blood cells and oxygen to wounds, speeding healing, a new study suggests.
A new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient’s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing.
A new study from the University of California, Irvine shows that compounds in both green and black tea relax blood vessels by activating ion channel proteins in the blood vessel wall. The discovery helps explain the antihypertensive properties of tea and could lead to the design of new blood pressure-lowering medications.
In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.
UC San Diego scientists have created new brain maps featuring unprecedented detail. The insights provided by the new maps are helping answer questions about blood supply and how more active parts of the brain are kept nourished versus less demanding areas.
A comprehensive review of the current CRISPR clinical trials landscape, covering progress on blood disorders, cancers, eye disease, chronic infection, rare protein-folding disease, and future prospects.
In presentations at the American Association for the Advancement of Science’s annual meeting, researchers argued that mathematics can help explain and predict those breakdowns, potentially offering new ways of treating the systems to prevent or fix them when things go wrong.
At 31 weeks and 5 days pregnant with identical twins, Amberlyn Smith went to her bi-weekly ultrasound feeling confident. Just two weeks prior, both of the twins had grown appropriately and screening tests came back normal. But that day, Dec. 23, there was a clear discrepancy in their size, as well as a notable abnormality in their blood flow. Smith was immediately sent to see an intervention specialist with UTHealth at Children’s Memorial Hermann Hospital, where she emergently delivered the twins the next morning, on Christmas Eve.
Utah researchers report significant new insights into the development of blood cancers. Comparing DNA data in people with and without blood disorders, the researchers discovered genetic mutations in about 2% of the presumably healthy participants that were identical to those frequently observed in the cancer patients. These findings provide new clues about mutations that may initiate cancer development and those that may help cancer progress.
There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States. A new preliminary study has found that they are not associated with an increased risk of intracerebral hemorrhage, the deadliest kind of stroke. The preliminary study released today, February 25, 2021, will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
Researchers have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give doctors an opportunity to intervene and prevent permanent damage, potentially using an existing medication.
Scientists at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified the specialized environment, known as a niche, in the bone marrow where new bone and immune cells are produced. The study, published in Nature, also shows that movement-induced stimulation is required for the maintenance of this niche, as well as the bone and immune-forming cells that it contains. Together, these findings identify a new way that exercise strengthens bones and immune function.
A complete blood count can help ascertain the health of a patient and typically includes an estimate of the hemoglobin concentration, which can indicate several conditions, including anemia, polycythemia, and pulmonary fibrosis. In AIP Advances, researchers describe a new AI-powered imaging-based tool to estimate hemoglobin levels. The setup was developed in conjunction with a microfluidic chip and an AI-powered automated microscope that was designed for deriving the total as well as differential counts of blood cells.
A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans.
A potentially dangerous side effect of testosterone therapy for transgender men is an increase in red blood cells that can raise the risk of blood clots, heart attack or stroke, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.
The National Institutes of Health (NIH) has awarded a $2.1 million, four-year research grant to Anirban Sen Gupta at Case Western Reserve University in Cleveland, Ohio, and collaborators at the University of Michigan and University of North Carolina, to advance the design of artificial platelets that can promote and stabilize clots to stop bleeding.
Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.
The research team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results.
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation.
A team of researchers from the Case Western Reserve University School of Medicine, Case School of Engineering and Louis Stokes Cleveland VA Medical Center is developing a blood-test device as an early warning system to help prevent pressure injuries.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right